Fig. 3From: Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysisThe safety outcomes of infections and infestations (a), major adverse cardiovascular events (b), deep vein thrombosis (c) and pulmonary embolism (d)Back to article page